This communication describes preliminary studies of the authors directed towards the possibility of practical implementation of the idea to design efficient antitumor drugs based on hybrid molecules composed of fullerene С60 and quadricyclanes. The essence of the proposed idea is that these hybrid molecules are able to cleave DNA owing to the fullerene moiety they contain and simultaneously to thermally affect tumor cells via cleavage of the carbon-carbon bond in quadricyclanes under the action of Pd and Pt ions. As a result, testing of the cytotoxic activity in vitro for a number of fullerene С60 hybrids with the norbornadiene or quadricyclane moieties against the human T-lymphoblastic leukemia cells (Jurkat cells) in combination of the known cisplatin drug, which was taken as the source of Pt ions, showed a statistically reliable dose-dependent increase in the number of dead cells in each group, which were formed according to the amount of cisplatin added, in comparison with the control, that is, cells treated with cisplatin or quadricyclane fullerene derivatives alone.
Keywords: Fullerene; quadricyclane; hybrid molecule; cisplatine; antitumor drugs
|Format: DOC||Size: 1.8 MB||Download|
When a peer-reviewed version of this preprint is available in the Beilstein Journals, this information will be updated in the information box above. If no peer-reviewed version is available, please cite this preprint using the following information:
Dzhemilev, U. M.; Khuzin, A. A.; Akhmetov, A. R.; D'yakonov, V. A.; Dzhemileva, L. U.; Yunusbaeva, M. M.; Tuktarov, A. R. Beilstein Arch. 2019, 201918. doi:10.3762/bxiv.2019.18.v1
|Download RIS (Reference Manager)||Download BIB (BIBTEX)|